These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22192174)

  • 1. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.
    Rosencher N; Albaladejo P
    Expert Opin Pharmacother; 2012 Feb; 13(2):217-26. PubMed ID: 22192174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE; Spinler SA
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing postsurgical venous thromboembolism: pharmacological approaches.
    Tufano A; Coppola A; Cerbone AM; Ruosi C; Franchini M
    Semin Thromb Hemost; 2011 Apr; 37(3):252-66. PubMed ID: 21455859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
    Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
    J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
    Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
    Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate in venous thromboembolism.
    Ferrer E
    Drugs Today (Barc); 2009 Oct; 45(10):715-24. PubMed ID: 20069135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
    Eriksson BI; Dahl OE; Rosencher N; Clemens A; Hantel S; Kurth AA
    Thromb Res; 2012 Dec; 130(6):871-6. PubMed ID: 22995531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
    Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
    Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
    ; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
    J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal profiles of anticoagulants.
    Harder S
    J Clin Pharmacol; 2012 Jul; 52(7):964-75. PubMed ID: 21610202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention].
    Antonijević N; Kanjuh V; Živković I; Jovanović L; Vukčević M; Apostolović M
    Srp Arh Celok Lek; 2015; 143(3-4):230-6. PubMed ID: 26012138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.